Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Total Current Liabilities (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Total Current Liabilities for 15 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 66.97% to $1.6 million in Q4 2025 year-over-year; TTM through Oct 2025 was $1.6 million, a 66.97% decrease, with the full-year FY2025 number at $2.9 million, down 60.73% from a year prior.
  • Total Current Liabilities was $1.6 million for Q4 2025 at PharmaCyte Biotech, up from $1.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $7.5 million in Q1 2024 to a low of $186122.0 in Q4 2021.
  • A 5-year average of $2.4 million and a median of $1.1 million in 2022 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: soared 1165.17% in 2024, then crashed 85.8% in 2025.
  • PharmaCyte Biotech's Total Current Liabilities stood at $186122.0 in 2021, then surged by 604.45% to $1.3 million in 2022, then surged by 299.62% to $5.2 million in 2023, then dropped by 8.84% to $4.8 million in 2024, then crashed by 66.97% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Total Current Liabilities are $1.6 million (Q4 2025), $1.1 million (Q3 2025), and $2.9 million (Q2 2025).